Filling baby bottles and treating disease... these are the habits of Abbott. Abbott Laboratories is a top health care products manufacturer. Its nutritional products division makes such well-known brands as Similac infant formula and the Ensure line of nutrition supplements, while its drug division sells branded generic medicines (such as antibiotics and gastroenterology medicines) in international markets. The company also makes diagnostic instruments (including tests and assays), vascular medical devices such as its Xience drug-eluting stents, and the FreeStyle diabetes care line, as well as eye care products. Abbott spun off its non-generic pharmaceutical operations into AbbVie in 2013.
After more than a year of planning, Abbott separated its medical and pharmaceutical operations in January 2013 by distributing shares of the newly public AbbVie to its shareholders. Flatly put, the split separated Abbott's stable business from its riskier operations -- while the AbbVie pharma operations accounted for roughly 45% of Abbott's revenues, its R&D work was inherently more expensive and riskier, and a number of its commercial products face patent expiration over the next few years.
The Abbott name sticks with the businesses that previously made up its diversified medical products division, including its nutritional, branded generic pharmaceutical, diagnostic, and vascular businesses (the new operating units). Each unit previously accounted for about 10% to 15% of the company's revenues. The nutritionals business is the largest operating segment following the AbbVie spinoff, with branded generic pharmaceuticals, now called Established Pharmaceutical Products, and Diagnostic Products tied for second.
Drug-coated stent Xience is one of the company's top products and key to its growth initiatives. The vascular segment makes other devices for coronary, endovascular, vessel closure, and structural heart procedures. One of its pipeline products is a first-of-its-kind drug eluting, bioreabsorbable, vascular scaffolding. Meanwhile, the diagnostic segment's products include point-of-care tests, molecular diagnostic products, and information management systems for diagnostic laboratories.
Abbott also makes diabetic testing products through its Abbott Diabetes Care unit, and it makes equipment for cataract and vision correction procedures (including LASIK equipment) through its Abbott Medical Optics subsidiary.
Abbott's products are sold in more than 150 countries. The company earns about 30% of revenues in the domestic market, with the remainder coming from countries including Japan, the Netherlands, Germany, France, Italy, and Canada. Abbott is working to grow sales in emerging markets such as Brazil, China, India, and Russia.
Sales and Marketing
Abbott conducts distribution operations both from its own distribution centers and from third-party distribution partners. Established pharmaceutical and nutritional customers include health care organizations, wholesalers, retailers, government agencies, and third-party distribution entities. Diagnostic and vascular products are sold to blood banks, hospitals, physicians, plasma protein therapeutic companies, and commercial laboratories.
In the face of multiple challenges, Abbott has been standing strong in the global business market in recent years. However, in 2013 revenue decreased by 45%, from $39 billion to $21.8 billion, due to the AbbVie spinoff. Sales in emerging markets did rise by 11%. The spinoff, and removal of AbbVie's income from the books, also hit net income, causing a drop of 57% to $2.6 billion. Of course, cash from operations also tumbled, by $6 billion to $3.3 billion.
Across the years, Abbott has made acquisitions and strategic alliances (in fields including research and marketing) to bolster its offerings and its geographic presence. After swallowing up several businesses, Abbott reshuffled its organization to help it run like the well-oiled giant it is, conducting job cuts and plant consolidations in the US and Europe from 2010 to 2012. Its biggest move was spinning off its branded pharmaceutical operations as AbbVie. AbbVie took the potential rewards of discovering a blockbuster drug but also the high risk and costs of R&D.
In the R&D realm, Abbott is hard at work on developing next-generation Xience products that include Xience nano, a version of the product for use in small vessels and Xience PRIME, a next-generation version Xience being tested in a range of sizes including small vessel and long lengths. In addition, Abbott has steadily grown its medical device offerings for other therapeutic applications.
Abbott is also widening its offering of clinical diagnostics tools, including the introduction of laboratory software to boost diagnostic data management capabilities.
Product development has also led to new nutritional product launches, such as new Ensure Complete shakes and Perfectly Simple (gluten and preservative-free) ZonePerfect protein bars launched in 2012. To further bolster the nutritional business, Abbott built a new manufacturing plant in Ohio, and opened its first nutritional R&D center in India.
In 2015 Abbott sold its non-US developed markets specialty and branded generics operations to Mylan. The sale included a portfolio of more than 100 pharmaceutical products in markets including Europe, Japan, Canada, Australia, and New Zealand; upon closing of the deal, Abbott received a 21% stake in the combined company.
Mergers and Acquisitions
In 2010 Abbott moved to bolster its position in the growing field of laboratory informatics by acquiring Tel Aviv-based STARLIMS Technologies, a provider of laboratory information management systems (LIMS), for about $123 million in cash. STARLIMS began buying out some of its longtime distribution partners in 2012 as part of its efforts to expand its LIMS business in Europe and emerging markets in Latin America and Africa.
The company also acquired several pharmaceutical businesses during 2010. Some of these operations were included in the AbbVie spinoff, while others bolstered Abbott's generic drug manufacturing operations.
The company struck two deals in 2013: Abbott purchased IDEV Technologies, a developer of radiology and surgery-related peripheral devices, for some $310 million to grow in the peripheral technology market. It also acquired OptiMedica for some $250 million to enter the laser cataract surgery market.
The spree continued in 2014 when the company doubled its operations in Latin America and upped its commitment to fast-growing markets by paying around $3 million, including debt, for CFR Pharmaceuticals. The Chile-based branded-pharmaceutical maker has manufacturing facilities in Chile, Colombia, Peru, and Argentina. Later that year Abbott acquired a controlling stake of Russian pharmaceutical maker Veropharm. The $305 million deal added manufacturing capabilities in Russia and broadened Abbott's presence in that country. At year-end, Abbott bought private medical device company Topera ($250 million), a developer of electrophysiology technologies to detect and treat atrial fibrillation.